Eddy S Yang Selected Research

Phosphotransferases (Kinase)

1/2022	An in vivo model of glioblastoma radiation resistance identifies long noncoding RNAs and targetable kinases.
1/2020	Therapeutically actionable PAK4 is amplified, overexpressed, and involved in bladder cancer progression.
3/2017	Kinase analysis of penile squamous cell carcinoma on multiple platforms to identify potential therapeutic targets.
3/2017	MARCKS phosphorylation is modulated by a peptide mimetic of MARCKS effector domain leading to increased radiation sensitivity in lung cancer cell lines.
1/2016	Kinase Gene Expression Profiling of Metastatic Clear Cell Renal Cell Carcinoma Tissue Identifies Potential New Therapeutic Targets.
3/2015	Targeting the effector domain of the myristoylated alanine rich C-kinase substrate enhances lung cancer radiation sensitivity.
6/2014	Kinomic exploration of temozolomide and radiation resistance in Glioblastoma multiforme xenolines.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Eddy S Yang Research Topics

Disease

72	Neoplasms (Cancer) 05/2024 - 01/2002
16	Breast Neoplasms (Breast Cancer) 07/2023 - 11/2008
12	Prostatic Neoplasms (Prostate Cancer) 01/2023 - 01/2002
11	Head and Neck Neoplasms (Head and Neck Cancer) 10/2023 - 07/2009
9	Squamous Cell Carcinoma of Head and Neck 01/2021 - 06/2011
8	Ovarian Neoplasms (Ovarian Cancer) 01/2020 - 09/2012
7	Adenocarcinoma 09/2023 - 03/2015
7	Carcinoma (Carcinomatosis) 01/2020 - 09/2014
6	Carcinogenesis 02/2023 - 07/2013
6	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2020 - 06/2011
5	Triple Negative Breast Neoplasms 08/2021 - 01/2021
4	Body Weight (Weight, Body) 01/2020 - 01/2017
3	DNA Repair-Deficiency Disorders (Chromosome Instability Syndromes) 07/2023 - 12/2015
3	Melanoma (Melanoma, Malignant) 01/2022 - 05/2020
3	Glioblastoma (Glioblastoma Multiforme) 01/2022 - 06/2012
2	Hypoxia (Hypoxemia) 02/2022 - 01/2022
2	Colonic Neoplasms (Colon Cancer) 01/2022 - 08/2010
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2022 - 07/2021
2	Renal Cell Carcinoma (Grawitz Tumor) 01/2021 - 01/2016
2	Weight Loss (Weight Reduction) 01/2020 - 10/2017
2	Ascites 01/2020 - 12/2016
2	Lung Neoplasms (Lung Cancer) 03/2017 - 03/2015
2	Brain Neoplasms (Brain Tumor) 01/2011 - 05/2009
1	Biliary Tract Neoplasms (Biliary Tract Cancer) 05/2024
1	Gastrointestinal Hemorrhage (Hematochezia) 09/2023
1	Anorexia 01/2022
1	Anemia 01/2022
1	Nausea 01/2022
1	Breast Ductal Carcinoma 01/2022
1	Lobular Carcinoma 01/2022
1	Fatigue 01/2022
1	Vomiting 01/2022
1	Exanthema (Rash) 01/2022

Drug/Important Bio-Agent (IBA)

17	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2021 - 01/2011
12	Proteins (Proteins, Gene)FDA Link 10/2021 - 08/2010
10	DNA (Deoxyribonucleic Acid)IBA 02/2022 - 06/2012
9	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 07/2023 - 01/2011
8	Biomarkers (Surrogate Marker)IBA 01/2022 - 06/2011
8	veliparibIBA 01/2021 - 01/2011
8	Cetuximab (Erbitux)FDA Link 01/2021 - 06/2009
7	Phosphotransferases (Kinase)IBA 01/2022 - 06/2014
5	Gemcitabine FDA Link 05/2024 - 01/2018
5	olaparibIBA 01/2023 - 09/2012
5	ErbB Receptors (EGF Receptor)IBA 01/2022 - 11/2008
5	Cisplatin (Platino)FDA LinkGeneric 01/2021 - 08/2010
4	Trastuzumab (Herceptin)FDA Link 05/2024 - 01/2018
4	(+)-JQ1 compoundIBA 05/2024 - 06/2019
4	RNA (Ribonucleic Acid)IBA 05/2024 - 01/2016
4	Messenger RNA (mRNA)IBA 01/2021 - 04/2015
4	AndrogensIBA 02/2017 - 01/2002
3	1,2- di- (4- sulfamidophenyl)- 4- butylpyrazolidine- 3,5- dione (DSB)IBA 02/2022 - 01/2011
3	Small Interfering RNA (siRNA)IBA 01/2022 - 06/2011
3	Histones (Histone)IBA 01/2021 - 01/2014
3	prexasertibIBA 01/2021 - 01/2017
3	CateninsIBA 01/2020 - 12/2016
3	Myristoylated Alanine-Rich C Kinase SubstrateIBA 03/2017 - 06/2012
3	Poly (ADP-Ribose) Polymerase-1IBA 01/2017 - 11/2013
3	Vitamin D FDA LinkGeneric 12/2015 - 01/2002
2	CholesterolIBA 05/2024 - 07/2021
2	Immune Checkpoint InhibitorsIBA 01/2024 - 01/2022
2	Monoclonal AntibodiesIBA 04/2023 - 08/2021
2	Hormones (Hormone)IBA 04/2023 - 11/2022
2	EndoglinIBA 04/2023 - 01/2013
2	Everolimus FDA Link 04/2023 - 01/2021
2	Phenobarbital (Luminal)FDA Link 04/2023 - 04/2015
2	Cell-Free Nucleic AcidsIBA 02/2023 - 01/2018
2	fluoromisonidazoleIBA 02/2022 - 01/2022
2	human ERBB2 proteinIBA 01/2022 - 12/2020
2	Immunoconjugates (Immunoconjugate)IBA 08/2021 - 01/2021
2	Maytansine (Maitansine)IBA 08/2021 - 07/2021
2	EnzymesIBA 01/2021 - 11/2013
2	PlatinumIBA 01/2020 - 01/2013
2	Prostate-Specific Antigen (Semenogelase)IBA 01/2019 - 04/2018
2	Niclosamide FDA Link 10/2018 - 12/2016
2	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 03/2017 - 01/2011
2	Peptides (Polypeptides)IBA 03/2017 - 03/2015
2	Cyclin-Dependent Kinases (cdk Proteins)IBA 07/2004 - 11/2003
2	Cholecalciferol (Vitamin D3)FDA Link 11/2003 - 01/2002
1	pertuzumabIBA 05/2024
1	1,4,7- triazacyclononane- N,N',N''- triacetic acid (NOTA)IBA 01/2024
1	Granzymes (Granzyme)IBA 01/2024
1	cyclopropapyrroloindoleIBA 01/2024
1	SteroidsIBA 09/2023
1	niraparibIBA 07/2023
1	alovudineIBA 07/2023
1	Letrozole (Femara)FDA LinkGeneric 04/2023
1	carotuximabIBA 04/2023
1	Interleukin-2 (IL2)IBA 02/2022
1	TH 302IBA 01/2022
1	Estrogen ReceptorsIBA 01/2022
1	ruxolitinibIBA 01/2022
1	AfatinibIBA 01/2022
1	N-vinyl-2-pyrrolidinoneIBA 01/2022

Therapy/Procedure

31	Therapeutics 07/2023 - 08/2007
18	Radiotherapy 01/2024 - 06/2011
6	Drug Therapy (Chemotherapy) 04/2023 - 07/2009
5	Precision Medicine 02/2023 - 10/2015
2	Immunotherapy 02/2023 - 01/2022
2	Neoadjuvant Therapy 11/2022 - 01/2018
2	Caloric Restriction 01/2020 - 10/2017